MedTrace Logo

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

NCT01009086 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 615

Last updated 2015-03-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effectiveness (improvement of signs and symptoms) and safety of ustekinumab in participants with active psoriatic arthritis.

Conditions

  • Arthritis, Psoriatic

Interventions

DRUG

Placebo

SC injections

DRUG

Ustekinumab 45 mg

SC injections

DRUG

Ustekinumab 90 mg

SC injections

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-10-31
Completion
2013-05-31

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • Finland
  • Germany
  • Hungary
  • Latvia
  • Lithuania
  • New Zealand
  • Poland
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01009086 on ClinicalTrials.gov